GlobalData on MSN
FDA approves AbbVie’s Rinvoq for inflammatory bowel disease
The US Food and Drug Administration (FDA) has approved AbbVie’s supplemental new drug application, updating the indication ...
The label update provides an option for patients who have received at least 1 approved systemic therapy if TNF blockers are clinically inadvisable.
Updated indication allows the use of RINVOQ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom ...
24/7 Wall St. on MSN
5 Safe Forever Dividend Stocks To Buy Now and Hold For Life
At 24/7 Wall St., we have closely followed dividend-paying stocks for over 15 years. With a growing audience of savvy Baby ...
Everyday Health on MSN
7 Myths About Ankylosing Spondylitis, Debunked
Ankylosing spondylitis is a type of inflammatory arthritis that is often misunderstood. Learn the facts behind the misinformation and myths about this chronic condition.
The updated indication for the JAK inhibitor allows use in patients with moderately to severely active ulcerative colitis and Crohn’s disease after one systemic therapy if TNF blockers are inadvisable ...
Insurance may cover Zepbound (tirzepatide) depending on your plan and the specific condition being treated. To determine whether your plan covers Zepbound, contact your insurance provider directly. If ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback